<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="260">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00075387</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU-922</org_study_id>
    <secondary_id>ONC-02059-L</secondary_id>
    <secondary_id>922</secondary_id>
    <secondary_id>7328</secondary_id>
    <nct_id>NCT00075387</nct_id>
  </id_info>
  <brief_title>Treating Patients With High-Grade Glioma With IA Carboplatin-based Chemotherapy, With or Without Sodium Thiosulfate</brief_title>
  <official_title>Phase II Clinical Trial Of Patients With High-Grade Glioma Treated With Intra-Arterial Carboplatin-Based Chemotherapy, Randomized To Treatment With Or Without Delayed Intravenous Sodium Thiosulfate As A Potential Chemoprotectant Against Severe Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and
      etoposide phosphate, work in different ways to stop tumor cells from dividing so they stop
      growing or die. Combining more than one drug (combination chemotherapy) and giving them in
      different ways may kill more tumor cells. Chemoprotective drugs, such as sodium thiosulfate,
      may protect blood platelets from the side effects of chemotherapy.

      PURPOSE: This randomized phase II trial is studying combination chemotherapy and sodium
      thiosulfate to see how well they work compared to combination chemotherapy alone in treating
      patients with high-grade glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the effect of delayed administration of high-dose sodium thiosulfate on
           platelet counts in patients with high-grade glioma undergoing treatment with
           carboplatin, cyclophosphamide, and etoposide or etoposide phosphate.

      Secondary

        -  Determine the effect of delayed administration of high-dose sodium thiosulfate on
           granulocyte and erythrocyte counts in patients treated with this chemotherapy regimen.

        -  Determine the tumor response in patients treated with this chemotherapy regimen with or
           without delayed high-dose sodium thiosulfate.

        -  Determine hearing changes at higher frequencies in the standard testing range (i.e.,
           4,000 and 8,000 Hz) and at higher frequencies above standard testing range (i.e., 9,000
           and 16,000 Hz) in patients treated with these regimens.

        -  Determine the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      histology type (glioblastoma multiforme vs other high-grade glioma). Patients are randomized
      to 1 of 2 treatment arms (Arm 1: no STS or Arm 2: STS).

        -  Arm I: Patients receive cyclophosphamide IV over 10 minutes, etoposide phosphate IV
           over 10 minutes (or etoposide IV), and carboplatin intra-arterially over 10 minutes on
           day 1. Beginning on day 3, patients receive filgrastim (G-CSF) subcutaneously once
           daily for 7-10 days until blood counts recover. Alternatively, one dose of Neulasta
           (Pegfilgrastim) instead of G-CSF 24-72 hrs after chemotherapy.

        -  Arm II: Patients receive cyclophosphamide, etoposide phosphate or etoposide and
           carboplatin as in arm 1. At 4 and 8 hours after carboplatin administration, patients
           receive high-dose sodium thiosulfate IV over 15 minutes.  Then, G-CSF as in arm 1.
           Alternatively, one dose of Neulasta (Pegfilgrastim) instead of G-CSF 24-72 hrs after
           chemotherapy.

      In both arms, treatment repeats every 4 weeks for 12 courses in the absence of disease
      progression or unacceptable toxicity.

      Quality of life is assessed at baseline, every 6 months during study treatment, and then
      within 30 days after the final study treatment.

      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Protection against severe thrombocytopenia as measured by the number of patients  requiring platelet transfusions based on labs obtained weekly during treatment</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response with or without sodium thiosulfate (STS) as measured by radiographic response from the first day of treatment until tumor progression</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of STS on granulocytes and erythrocytes as measured by complete blood count  lab values obtained weekly during treatment</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hearing changes assessed by audiology hearing test every 2 months during treatment</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EORTC QOL before treatment, at 6 months, and at completion of treatment</measure>
    <time_frame>Up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 10 minutes, etoposide phosphate IV over 10 minutes (or etoposide IV), and carboplatin intra-arterially over 10 minutes on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive cyclophosphamide, etoposide phosphate or etoposide, and carboplatin as in arm I.    At 4 and 8 hours  after carboplatin administration, patients  receive high-dose sodium thiosulfate IV over 15 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Dose: 400 mg/m2 infused IA. Every 4 weeks for up to 1 year.</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Dose: 660 mg/m2 infused IV. Every 4 weeks for up to 1 year.</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide phosphate</intervention_name>
    <description>Dose: 400mg/m2 infused IV. Etoposide may be used instead. Every 4 weeks for up to 1 year.</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Dose: 400mg/m2 infused IV every 4 weeks for up to 1 year. Etoposide phosphate may be given instead.</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium thiosulfate</intervention_name>
    <description>Dose: 4 hours after carboplatin = 20gms/m2
Dose: 8 hours after carboplatin = 16gms/m2</description>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>STS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Signed written informed consent form in accordance with institutional guidelines

          -  Histologically confirmed high-grade glioma by needle biopsy, open biopsy, or surgical
             resection

          -  Age 18 to 75 years

          -  Performance status ECOG 0-2 OR Karnofsky 50-100%

          -  WBC at least 2,500/mm^3

          -  Absolute granulocyte count at least 1,200/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin less than 2.0 mg/dL

          -  SGOT/SGPT less than 2.5 times upper limit of normal

          -  Creatinine less than 1.8 mg/dL

          -  Fertile patients must use effective contraception for at least 2 months before and
             during study participation

        EXCLUSION CRITERIA:

          -  Rapidly progressing CNS disease with associated neurological deterioration

          -  Uncontrolled clinically significant confounding medical condition within the past 30
             days such as congestive heart failure

          -  Pregnant or lactating, or positive serum HCG.

          -  Contraindications to the study medications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward A. Neuwelt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward A Neuwelt, MD</last_name>
    <phone>503-494-5626</phone>
    <email>neuwelte@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cynthia A Lacy, BSN</last_name>
    <phone>503-494-5626</phone>
    <email>lacyc@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Hunt, MD</last_name>
      <phone>612-626-0975</phone>
      <email>huntx188@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Brandt, BSN</last_name>
      <phone>612-624-8117</phone>
      <email>nbrandt10@umphysicians.umn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Hunt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Knight Cancer Institute at Oregon Hea</last_name>
      <phone>503-494-1080</phone>
      <email>trials@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Edward A Neuwelt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.gov/clinicaltrials/OHSU-7328</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQÂ® database</description>
  </link>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 30, 2013</lastchanged_date>
  <firstreceived_date>January 9, 2004</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thrombocytopenia</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
